DE69316660D1 - Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten - Google Patents

Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten

Info

Publication number
DE69316660D1
DE69316660D1 DE69316660T DE69316660T DE69316660D1 DE 69316660 D1 DE69316660 D1 DE 69316660D1 DE 69316660 T DE69316660 T DE 69316660T DE 69316660 T DE69316660 T DE 69316660T DE 69316660 D1 DE69316660 D1 DE 69316660D1
Authority
DE
Germany
Prior art keywords
treatment
terfanadine
metabolites
optically pure
allergic diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69316660T
Other languages
English (en)
Other versions
DE69316660T2 (de
DE69316660T3 (de
Inventor
James Young
Nancy Gray
Raymond Woosley
Yiwang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Georgetown University
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27129882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69316660(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Georgetown University, Sepracor Inc filed Critical Georgetown University
Application granted granted Critical
Publication of DE69316660D1 publication Critical patent/DE69316660D1/de
Publication of DE69316660T2 publication Critical patent/DE69316660T2/de
Publication of DE69316660T3 publication Critical patent/DE69316660T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DE69316660T 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten Expired - Lifetime DE69316660T3 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92418292A 1992-08-03 1992-08-03
US92415692A 1992-08-03 1992-08-03
PCT/US1993/007260 WO1994003170A1 (en) 1992-08-03 1993-08-03 Terfenadine metabolites and their optically pure isomers for treating allergic disorders

Publications (3)

Publication Number Publication Date
DE69316660D1 true DE69316660D1 (de) 1998-02-26
DE69316660T2 DE69316660T2 (de) 1998-05-07
DE69316660T3 DE69316660T3 (de) 2001-04-05

Family

ID=27129882

Family Applications (5)

Application Number Title Priority Date Filing Date
DE9320925U Expired - Lifetime DE9320925U1 (de) 1992-08-03 1993-08-03 Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
DE0701443T Pending DE701443T1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten
DE69316660T Expired - Lifetime DE69316660T3 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
DE69334145T Expired - Lifetime DE69334145T2 (de) 1992-08-03 1993-08-03 Terfenadincarboxylat und die Behandlung von Hautreizung
DE69334008T Expired - Lifetime DE69334008T2 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE9320925U Expired - Lifetime DE9320925U1 (de) 1992-08-03 1993-08-03 Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
DE0701443T Pending DE701443T1 (de) 1992-08-03 1993-08-03 Terfanadin Metaboliten und deren optische reine Isomeren zur Behandlung vonallegischen Krankheiten

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69334145T Expired - Lifetime DE69334145T2 (de) 1992-08-03 1993-08-03 Terfenadincarboxylat und die Behandlung von Hautreizung
DE69334008T Expired - Lifetime DE69334008T2 (de) 1992-08-03 1993-08-03 Terfenadin-Carboxylat und die Behandlung von allergischen Erkrankungen

Country Status (24)

Country Link
US (1) US5375693A (de)
EP (4) EP0701443B2 (de)
JP (6) JP3041954B2 (de)
KR (1) KR950702420A (de)
AT (3) ATE162399T1 (de)
AU (3) AU675240B2 (de)
BR (1) BR9306841A (de)
CA (1) CA2141572C (de)
CZ (1) CZ27495A3 (de)
DE (5) DE9320925U1 (de)
DK (3) DK0815860T3 (de)
ES (3) ES2086270T5 (de)
FI (1) FI950467A (de)
GB (1) GB2284351B (de)
GR (3) GR960300024T1 (de)
HK (1) HK1045806B (de)
HU (1) HU226242B1 (de)
NO (1) NO310644B1 (de)
PL (1) PL174373B1 (de)
PT (2) PT1214937E (de)
RO (1) RO116043B1 (de)
RU (1) RU2167657C2 (de)
SK (1) SK12495A3 (de)
WO (1) WO1994003170A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ251834A (en) * 1992-05-11 1997-07-27 Merrell Dow Pharma Use of acid derivatives of terfenadine as antihistamines
DE9320925U1 (de) * 1992-08-03 1995-08-31 Sepracor Inc Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
US20020007068A1 (en) 1999-07-16 2002-01-17 D'ambra Thomas E. Piperidine derivatives and process for their production
EP0723958A1 (de) * 1993-06-24 1996-07-31 Albany Molecular Research, Inc. Synthese von praktisch reinen Terfenadinderivaten
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2449419C (en) 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5455049A (en) * 1995-01-04 1995-10-03 Ascent Pharmaceuticals, Inc. Terfenadine oral powder
MX9706449A (es) * 1995-02-28 1997-11-29 Hoechst Marion Roussel Inc Composicion farmaceutica para compuestos de piperidinalcanol.
GB9513972D0 (en) * 1995-07-08 1995-09-06 Merck Sharp & Dohme Pharmaceutical compositions
US5906747A (en) * 1995-11-13 1999-05-25 Biosepra Inc. Separation of molecules from dilute solutions using composite chromatography media having high dynamic sorptive capacity at high flow rates
US6486177B2 (en) 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US5908850A (en) * 1995-12-04 1999-06-01 Celgene Corporation Method of treating attention deficit disorders with d-threo methylphenidate
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US6355656B1 (en) 1995-12-04 2002-03-12 Celgene Corporation Phenidate drug formulations having diminished abuse potential
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5733756A (en) * 1996-01-05 1998-03-31 Celgene Corporation Lactams and processes for stereoselective enrichment of lactams, amides, and esters
US6153754A (en) 1995-12-21 2000-11-28 Albany Molecular Research, Inc. Process for production of piperidine derivatives
US6201124B1 (en) 1995-12-21 2001-03-13 Albany Molecular Research, Inc. Process for production of piperidine derivatives
ES2124167B1 (es) * 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
US5925761A (en) * 1997-02-04 1999-07-20 Sepracor Inc. Synthesis of terfenadine and derivatives
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
ATE238773T1 (de) * 1997-08-26 2003-05-15 Aventis Pharma Inc Arzneimittel für die kombination piperidinoalkanol-dekongestivum
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
DE19913862C2 (de) * 1999-03-26 2003-04-10 Forschungszentrum Juelich Gmbh Verfahren zur biokatalysierten Umsetzung schlecht wasserlöslicher Substanzen
DE10007203A1 (de) * 2000-02-17 2001-08-23 Asta Medica Ag Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
US6613907B2 (en) 2000-11-08 2003-09-02 Amr Technology, Inc. Process for the production of piperidine derivatives with microorganisms
WO2002080857A2 (en) * 2001-04-09 2002-10-17 Teva Pharmaceutical Industries Ltd. Polymorphs of fexofenadine hydrochloride
US20030021849A1 (en) * 2001-04-09 2003-01-30 Ben-Zion Dolitzky Polymorphs of fexofenadine hydrochloride
WO2003020274A1 (en) * 2001-08-30 2003-03-13 Aventis Pharmaceuticals Inc. Treatment of atopic dermatitis
US20040044038A1 (en) * 2002-06-10 2004-03-04 Barnaba Krochmal Polymorphic form XVI of fexofenadine hydrochloride
US20050026890A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4515121B2 (ja) 2004-03-15 2010-07-28 東芝テック株式会社 ワイヤドットプリンタヘッド及びワイヤドットプリンタ
JP4473021B2 (ja) 2004-03-22 2010-06-02 東芝テック株式会社 窒化層形成方法、磁気回路形成部材、アーマチュア、ワイヤドットプリンタヘッド及びワイヤドットプリンタ
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
KR20070007196A (ko) * 2004-04-26 2007-01-12 테바 파마슈티컬 인더스트리즈 리미티드 펙소페나딘 히드로클로라이드의 결정형 및 이의 제조 방법
US7498443B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of carebastine
US7498345B2 (en) 2004-09-17 2009-03-03 Albany Molecular Research, Inc. Process for production of piperidine derivatives
WO2006037042A1 (en) * 2004-09-28 2006-04-06 Teva Pharmaceutical Industries Ltd. Fexofenadine crystal form and processes for its preparation thereof
AU2005313887B2 (en) * 2004-12-09 2011-10-27 Celgene Corporation Treatment using D-threo methylphenidate
NZ568694A (en) 2005-11-09 2011-09-30 Zalicus Inc Method, compositions, and kits for the treatment of medical conditions
ES2534588T3 (es) * 2007-04-13 2015-04-24 Southern Research Institute Terfenadina como agente antiangiogénico
US20090076080A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched fexofenadine
WO2014052836A2 (en) 2012-09-27 2014-04-03 Dunman Paul M Methods and compositions for treating infection
CN115887456A (zh) 2015-03-26 2023-04-04 杰奎琳·M·艾弗森 抑制与宿醉相关的症状的方法和组合物
DE102017130361A1 (de) 2017-12-18 2019-07-04 Lsp Innovative Automotive Systems Gmbh Statorzahn und Stator mit guter elektrischer Isolierung und gleichzeitig sehr hoher Wärmeleitfähigkeit zur Leistungssteigerung von Elektromotoren

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US880801A (en) † 1908-03-03 Harold Larsen Vibrator.
US922890A (en) † 1907-03-26 1909-05-25 Peder Joergen Hansen Stream-motor.
US4254129A (en) * 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4552899A (en) † 1984-04-09 1985-11-12 Analgesic Associates Cough/cold mixtures comprising non-steroidal anti-inflammatory drugs
US4829064A (en) † 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4929605A (en) * 1987-10-07 1990-05-29 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol derivatives
US4996061A (en) † 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
JP3686950B2 (ja) * 1992-04-10 2005-08-24 メレル ファーマスーティカルズ インコーポレイテッド ピペリジン誘導体類の新規な方法
NZ251834A (en) 1992-05-11 1997-07-27 Merrell Dow Pharma Use of acid derivatives of terfenadine as antihistamines
DE9320925U1 (de) 1992-08-03 1995-08-31 Sepracor Inc Terfenadin-Metabolite und deren optisch reine Isomere für die Behandlung von allergischen Störungen
EP0723958A1 (de) * 1993-06-24 1996-07-31 Albany Molecular Research, Inc. Synthese von praktisch reinen Terfenadinderivaten
HU226037B1 (en) * 1993-06-25 2008-03-28 Aventis Inc Process for producing antihistaminic 4-diphenylmethyl/diphenylmethoxy piperidine derivatives and novel intermediates
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
CA2128821A1 (en) * 1993-07-27 1995-01-28 Dilip J. Gole Freeze-dried pharmaceutical dosage form and process for separation thereof
WO1995010278A1 (en) * 1993-10-15 1995-04-20 Hoechst Marion Roussel, Inc. Treatment of allergic disorders with terfenadine carboxylate

Also Published As

Publication number Publication date
WO1994003170A1 (en) 1994-02-17
DK1214937T3 (da) 2007-09-17
ATE363283T1 (de) 2007-06-15
AU1842999A (en) 1999-04-29
ES2257757T3 (es) 2006-08-01
DE69316660T2 (de) 1998-05-07
ES2086270T3 (es) 1998-03-01
NO950374D0 (no) 1995-02-01
DE9320925U1 (de) 1995-08-31
JP2000086513A (ja) 2000-03-28
GR960300024T1 (en) 1996-05-31
PT1214937E (pt) 2007-07-25
EP0815860A3 (de) 1998-01-14
EP0815860B1 (de) 2006-04-12
SK12495A3 (en) 1997-01-08
GR3026530T3 (en) 1998-07-31
ATE162399T1 (de) 1998-02-15
JPH08500348A (ja) 1996-01-16
DK0701443T3 (da) 1998-02-09
RU2167657C2 (ru) 2001-05-27
DE69334008D1 (de) 2006-05-24
ES2284740T3 (es) 2007-11-16
CA2141572A1 (en) 1994-02-17
RO116043B1 (ro) 2000-10-30
GB2284351B (en) 1996-11-27
JP2000086514A (ja) 2000-03-28
DK0815860T3 (da) 2006-08-14
EP1214937A2 (de) 2002-06-19
DE69334145T2 (de) 2008-01-24
AU4798693A (en) 1994-03-03
PL307339A1 (en) 1995-05-15
EP1214937A3 (de) 2002-10-30
DE69334145D1 (de) 2007-07-12
JP3288660B2 (ja) 2002-06-04
JP2000086515A (ja) 2000-03-28
DE701443T1 (de) 1997-01-30
FI950467A (fi) 1995-03-31
AU675240B2 (en) 1997-01-30
BR9306841A (pt) 1998-12-08
JP2000086516A (ja) 2000-03-28
HK1045806A1 (en) 2002-12-13
GB9502183D0 (en) 1995-03-22
EP0815860A2 (de) 1998-01-07
ES2086270T1 (es) 1996-07-01
DE69334008T2 (de) 2006-10-19
HU226242B1 (en) 2008-07-28
ES2086270T5 (es) 2001-02-01
EP0701443A1 (de) 1996-03-20
JP2000086512A (ja) 2000-03-28
NO950374L (no) 1995-03-29
JP3041954B2 (ja) 2000-05-15
JP3288662B2 (ja) 2002-06-04
EP0701443B1 (de) 1998-01-21
CA2141572C (en) 2001-02-06
NO310644B1 (no) 2001-08-06
DE69316660T3 (de) 2001-04-05
RU95107881A (ru) 1996-11-27
HU9500313D0 (en) 1995-03-28
GR3035417T3 (en) 2001-05-31
GB2284351A (en) 1995-06-07
JP3288661B2 (ja) 2002-06-04
EP0701443B2 (de) 2000-11-22
US5375693A (en) 1994-12-27
DK0701443T4 (da) 2000-12-18
EP1688142A1 (de) 2006-08-09
ATE322899T1 (de) 2006-04-15
AU7182296A (en) 1997-01-30
JP3037697B2 (ja) 2000-04-24
KR950702420A (ko) 1995-07-29
EP1214937B1 (de) 2007-05-30
HK1045806B (zh) 2008-03-14
PT815860E (pt) 2006-08-31
PL174373B1 (pl) 1998-07-31
CZ27495A3 (en) 1996-09-11
FI950467A0 (fi) 1995-02-02
HUT71889A (en) 1996-02-28

Similar Documents

Publication Publication Date Title
DE69316660D1 (de) Terfanadin Metaboliten und deren optisch reine Isomere zur Behandlung von allergischen Krankheiten
DE4394931T1 (de) Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: SEPRACOR INC., MARLBOROUGH, MASS., US

8366 Restricted maintained after opposition proceedings